生长抑素受体亚型在胰腺癌组织的表达研究  

Expression of somatostatin receptor subtypes in human pancreatic cancer

作　　者：何长生[1] 全竹富[1] 张新华[2] 孙桂勤[2] 李宁[1] 黎介寿[1] 

机构地区：[1]南京大学医学院临床学院(南京军区南京总医院)普通外科研究所,江苏南京210002 [2]南京大学医学院临床学院(南京军区南京总医院)病理科,江苏南京210002

出　　处：《肠外与肠内营养》2007年第3期144-148,共5页Parenteral & Enteral Nutrition

摘　　要：目的：探讨生长抑素受体亚型（SSTR1～5）在胰腺癌组织中的表达及临床病理学意义,为临床生长抑素治疗胰腺肿瘤提供理论依据。方法：采用免疫组化EnVision^TM＋法检测50例胰腺癌组织中生长抑素受体（SSTR）5种亚型的表达。结果：SSTR1～5亚型在胰腺癌组织中均有表达,但表达强弱有明显差异。SSTR1表达阳性率为50%,SSTR2为94%,SSTR3为82%,SSTR4为90%,SSTR5为96%。胰腺癌SSTR表达优势是SSTR5〉SSTR2〉SSTR4〉SSTR3〉SSTR1（P〈0.01）。胰腺癌SSTR各亚型表达阳性率与病人年龄、性别、肿瘤部位和大小、肿瘤组织分化程度及肿瘤分期无统计学意义（P〉0.05）。结论：胰腺癌组织中有SSTR1～5表达,可为将来生长抑素及其类似物治疗胰腺癌提供理论依据。免疫组化方法分析胰腺癌组织中SSTR各亚型表达,可作为病理学分析肿瘤组织中SSTR亚型表达的常规方法。Objective ： To detect the expression of SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 （ SSTR1- 5） in human pancreatic cancer and discuss their relationships with cliniopathological features. Methods ： Immunohistochemical staining of 5 SSTR subtypes was performed by the EnVision^TM＋ technique for paraffin sections of 50 eases of pancreatic cancer. The relationship between the 5 SSTR subtypes expression in pancreatic cancers and the clinieopathologieal parameters was analyzed. Results： The expression rate of somatostatin receptor subtype-1, subtype-2, subtype-3, subtype-4, subtype-5 in the specimens of pancreatic cancer was 50% , 94%., 82%, 90% and 96% ,respectively. The rank order of SSTR subtypes positive expression in pancreatic cancer tissues was SSTR5 〉 SSTR2 〉 SSTR4 〉 SSTR3 〉 SSTR1 （P 〈0.01 ）. No difference of SSTR1-5 expression rate between age, sex, location, tumor size, histological grading and pathological staging was found （P 〉 0.05 ）. Conclusion ： SSTR1-5 was detected in human pancreatic cancer, which provided evidence for SST and somatostatin analogs therapy in human pancreatic caneer in the future. The expression rate of SSTR1-5 did not correlate with age, sex, location, tumor size, histological grading and pathological staging of the pancreatic cancer.

关 键 词：生长抑素 生长抑素受体 胰腺癌 免疫组化 

分 类 号：R735.9[医药卫生—肿瘤]